{"@id":"https://bioecon.ru/technology/sarcopenia-myostatin-activin-therapeutics/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/sarcopenia-myostatin-activin-therapeutics/","json":"https://cn.bioecon.ru/api/v1/technology/sarcopenia-myostatin-activin-therapeutics/index.json"},"id":"sarcopenia-myostatin-activin-therapeutics","industries":["longevity"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/longevity/"],"suppliers":["https://bioecon.ru/companies/biohaven/","https://bioecon.ru/companies/hanmi-pharmaceutical/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/regeneron-pharmaceuticals/","https://bioecon.ru/companies/roche-holding/","https://bioecon.ru/companies/scholar-rock/","https://bioecon.ru/companies/bioage-labs/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/isomorphic-labs/","https://bioecon.ru/companies/algalif/","https://bioecon.ru/companies/codexis/"]},"maturity":4,"name":"肌少症与肌肉保护疗法（肌生成抑制素、激活素通路）","regions":["us","eu"],"risk":"high","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-09","entity":"hanmipharm.com","kind":"web","urls":["https://www.hanmipharm.com/science/pipeline/focused/hm500197.hm"]},{"date":"2026-11-09","entity":"pmc.ncbi.nlm.nih.gov","kind":"research","urls":["https://pmc.ncbi.nlm.nih.gov/articles/PMC12146653/"]},{"date":"2026-11-09","entity":"academic.oup.com","kind":"research","urls":["https://academic.oup.com/edrv/article/43/2/329/6370269","https://academic.oup.com/biomedgerontology/article/78/Supplement_1/32/7026116"]},{"date":"2026-11-09","entity":"atm.amegroups.org","kind":"web","urls":["https://atm.amegroups.org/article/view/153082/html"]}],"stages":[{"n":1,"title":"入组人群"},{"n":2,"title":"选择终点"},{"n":3,"title":"统一结局"}],"summary":"阻断肌肉生长负调节因子的药物；该领域多处于II期，许多候选药难以进入III期，因为肌肉量增加未必转化为功能改善。","url":"/technology/sarcopenia-myostatin-activin-therapeutics/","verified":"2026-11-09"}